Correlation coefficients will be calculated for relationships between adherence, patient characteristics, disease characteristics, side effects, quality of life, patient beliefs and attitude towards disease and medication, dose adjustments and plasma concentration of erlotinib in patients with NSCLC.
Descriptive statistics were calculated to describe the patient characteristics, side effect, and medication adherence for the entire sample.
Angiotensin-converting enzyme inhibitors (ACE-I) are considered safe, but they are associated with characteristic side effects, namely cough and angioedema, usually requiring discontinuation.
Cetuximab does not appear to increase the intensity or frequency of the characteristic side effects of cytotoxic chemotherapy.
Thus, NAVA not only prevents lung overdistension and potentially diaphragm disuse, but also the characteristic side effects of positive pressure ventilation on right ventricular function.
However, microtubule destabilising VDAs appear to have some characteristic side effects, particularly cardiovascular toxicity (Beerepoot et al, 2006; van Heeckeren et al, 2006).
We also investigated the association with Hemoglobin, S-creatinine and immunosuppressive regimen (tacrolimus/prednisolone vs. ciclosporin/prednisolone), possibly being able to capture the characteristic side effects of ciclosporin of gum and hair growth.
39, 40 Examples of radiologic immune-related response criteria and toxicity in patients with advanced melanoma treated with ipilimumab can be seen in the pictorial assay published by O'Regan et al. 41 Characteristic side effects from inhibition of CTLA-4 are called immune (or inflammation -related adverse events (inflammation -related
Further, the relationships between patient characteristics, disease characteristics, side-effects, quality of life, patient beliefs and attitude towards disease and medication, dose adjustments, reasons for discontinuation and plasma concentration of erlotinib will be explored.
Furthermore, the relationships between patient characteristics, disease characteristics, side-effects, quality of life, patient beliefs and attitude towards disease and medication, adherence, dose adjustments and plasma concentration of erlotinib in patients with NSCLC will be explored.
Panitumumab is associated with a well-defined adverse event profile (in particular, dermatologic toxicities, a characteristic side effect of EGFR inhibitors (Agero et al, 2006)), and it is important to understand how the impact of such toxicities weigh against the benefits of the drug.
